Sod1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SOD1 (Superoxide Dismutase 1) is a 154-amino acid, 15.9 kDa cytosolic enzyme that catalyzes the dismutation of superoxide anion radicals (O₂⁻) into hydrogen peroxide (H₂O₂) and molecular oxygen. This detoxification reaction is a critical component of cellular antioxidant defense. SOD1 was the first gene linked to familial amyotrophic lateral sclerosis (ALS), and over 190 pathogenic mutations have been identified, making it one of the most extensively studied proteins in neurodegeneration research.
SOD1 is a 154-amino acid protein with several key structural features:
- N-terminal region (1-80 aa): Contains the dimer interface and metal-binding sites
- C-terminal region (81-154 aa): Stabilizes the dimer and contributes to substrate access
SOD1 requires metal ions for catalytic activity:
| Site |
Ion |
Role |
| Copper site |
Cu²⁺ |
Catalytic center for dismutation |
| Zinc site |
Zn²⁺ |
Structural stabilization |
| Disulfide bond |
Cys57-Cys146 |
Covalent dimer stabilization |
The "wild-type" SOD1 fold requires copper and zinc binding for proper folding and stability. Mutations can destabilize the structure even when metals are present.
SOD1 functions as a homodimer, with each monomer approximately 15.9 kDa. The dimer interface is critical for:
- Structural stability
- Substrate channeling
- Protection from aggregation
PDB structures: 1HL5, 1HL4, 1MKO, 1N19, and many mutant variants. These structures reveal:
- Greek key β-barrel fold
- Dimer interface spanning residues 49-53 and 123-153
- Loop structures (loop 4, loop 7) that can be disrupted by mutations
SOD1 catalyzes the dismutation reaction:
2 O₂⁻ + 2 H⁺ → H₂O₂ + O₂
This reaction occurs via a cyclic mechanism:
- Reduced SOD1 (Cu⁺) oxidizes superoxide to oxygen
- Oxidized SOD1 (Cu²⁺) reduces another superoxide to hydrogen peroxide
- Catalytic turnover requires alternating oxidation/reduction states of the copper ion
Beyond superoxide scavenging, SOD1 participates in:
- Redox signaling: Modulates cellular signaling through H₂O₂ production
- Cellular stress response: Upregulated under oxidative stress conditions
- Iron homeostasis: Interacts with iron regulatory proteins
- Mitochondrial function: Protects mitochondria from oxidative damage
- Axonal transport: Localizes to mitochondria-rich axonal regions
- Ubiquitously expressed in all tissues
- Highest expression in liver, erythrocytes, and brain
- In CNS: neurons and glia express SOD1
- Not enriched in motor neurons, yet mutations cause ALS — suggesting cell-type specific vulnerability
SOD1 was linked to familial ALS in 1993 (Rosen et al., Nature). Over 190 mutations have been identified:
- Autosomal dominant inheritance
- Accounts for ~12-20% of familial ALS
- Variable age of onset (30-70 years)
- Variable disease duration (1-20+ years)
SOD1 mutations cause ALS through multiple mechanisms:
Mutant SOD1 acquires novel toxic properties:
- Aggregation propensity: Many mutations increase misfolding and aggregation
- Oxidative damage: Enhanced peroxidation activity with H₂O₂
- Disrupted metal binding: Loss of catalytic metal coordination
- Dimer destabilization: Monomeric or off-pathway species
Some mutations reduce dismutase activity:
- Reduced capacity to detoxify superoxide
- Increased oxidative stress in motor neurons
- However, loss-of-function alone doesn't cause ALS (SOD1 knockout mice develop normally)
SOD1 mutants accumulate in mitochondria:
- Bind to mitochondria-specific proteins (Hsp60, VDAC)
- Impair electron transport chain function
- Disrupt calcium handling
- Activate apoptotic pathways
Mutant SOD1 in astrocytes and microglia:
- Accelerates disease progression in mouse models
- Secreted SOD1 can be taken up by wild-type neurons
- Activates non-neuronal cells to release toxic factors
SOD1 mutants disrupt:
- Anterograde transport of organelles
- Mitochondrial trafficking
- Neurotrophic factor delivery
SOD1 Transgenic Mice:
- G93A, G37R, G85R, and other mutant lines
- Develop progressive motor neuron disease
- Phenocopy human ALS
- Used extensively for therapeutic testing
- AAV-delivered shRNA/siRNA: Silence mutant SOD1 (e.g., tofersen targets SOD1)
- CRISPR-Cas9: Gene editing to correct mutations
- AAV-microRNA: Deliver anti-SOD1 constructs
- Copper chelators: Remove toxic copper
- Arsenic trioxide: Promotes proper folding
- Autophagy inducers: Clear mutant SOD1 aggregates
- Protein-protein interaction inhibitors: Block aggregation
- Active vaccination: Anti-SOD1 antibodies in trials
- Passive immunotherapy: Monoclonal antibodies against SOD1
- Tofersen (BIIB067): Antisense oligonucleotide for SOD1 ALS — showed slower decline in Phase 3 VALOR trial [1]
- Minocycline: Failed due to adverse effects
- Celastrol: Failed in clinical trials
- SOD1 activity is reduced in AD brains
- May contribute to oxidative stress
- Some studies suggest protective role against Aβ toxicity
- Reduced SOD1 activity in substantia nigra
- Possible interaction with α-synuclein
- Mitochondrial dysfunction parallels SOD1-ALS mechanisms
- FTD: Rare SOD1 mutations reported
- Charcot-Marie-Tooth disease: Some SOD1 mutations cause peripheral neuropathy
- Cancer: SOD1 overexpression in many cancers; role in tumor progression
The study of Sod1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:8374149 — Rosen et al., 1993, SOD1 mutations cause familial ALS
- PMID:15496877 — Valentine et al., 2004, SOD1 and ALS review
- PMID:17015226 — Boillee et al., 2006, Non-cell-autonomous toxicity
- PMID:24269473 — SOD1 structure and mutations
- PMID:32665412 — SOD1 therapeutic targets
- PMID:31061497 — Mutant SOD1 toxicity mechanisms
- PMID:20417254 — Mitochondrial dysfunction in SOD1-ALS
- PMID:23912775 — Axonal transport defects
- PMID:26282226 — Tofersen Phase 1/2 trial
- PMID:36952552 — Tofersen Phase 3 VALOR trial